Success Metrics

Clinical Success Rate
33.3%

Based on 1 completed trials

Completion Rate
33%(1/3)
Active Trials
4(44%)
Results Posted
200%(2 trials)
Terminated
2(22%)

Phase Distribution

Ph phase_1
7
78%
Ph phase_3
1
11%
Ph phase_2
1
11%

Phase Distribution

7

Early Stage

1

Mid Stage

1

Late Stage

Phase Distribution9 total trials
Phase 1Safety & dosage
7(77.8%)
Phase 2Efficacy & side effects
1(11.1%)
Phase 3Large-scale testing
1(11.1%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

25.0%

1 of 4 finished

Non-Completion Rate

75.0%

3 ended early

Currently Active

4

trials recruiting

Total Trials

9

all time

Status Distribution
Active(4)
Completed(1)
Terminated(3)
Other(1)

Detailed Status

Recruiting2
Active, not recruiting2
Terminated2
Completed1
unknown1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
4
Success Rate
33.3%
Most Advanced
Phase 3

Trials by Phase

Phase 17 (77.8%)
Phase 21 (11.1%)
Phase 31 (11.1%)

Trials by Status

completed111%
recruiting222%
unknown111%
withdrawn111%
active_not_recruiting222%
terminated222%

Recent Activity

4 active trials
Showing 5 of 9
active_not_recruitingphase_1

Testing a New Chemotherapy Drug, KRT-232 (AMG-232) in Combination With Decitabine and Venetoclax in Patients With Acute Myeloid Leukemia

NCT03041688
active_not_recruitingphase_1

Testing the Addition of an Anti-cancer Drug, Navtemadlin, to the Usual Treatments (Cytarabine and Idarubicin) in Patients With Acute Myeloid Leukemia

NCT04190550
terminatedphase_1

Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma

NCT03031730
terminatedphase_1

Testing the Ability of AMG 232 (KRT 232) to Get Into the Tumor in Patients With Brain Cancer

NCT03107780
recruitingphase_3

Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

NCT06479135
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT03041688Phase 1

Testing a New Chemotherapy Drug, KRT-232 (AMG-232) in Combination With Decitabine and Venetoclax in Patients With Acute Myeloid Leukemia

Active Not Recruiting
NCT04190550Phase 1

Testing the Addition of an Anti-cancer Drug, Navtemadlin, to the Usual Treatments (Cytarabine and Idarubicin) in Patients With Acute Myeloid Leukemia

Active Not Recruiting
NCT03031730Phase 1

Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma

Terminated
NCT03107780Phase 1

Testing the Ability of AMG 232 (KRT 232) to Get Into the Tumor in Patients With Brain Cancer

Terminated
NCT06479135Phase 3

Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

Recruiting
NCT03217266Phase 1

Navtemadlin and Radiation Therapy in Treating Patients With Soft Tissue Sarcoma

Completed
NCT05797831Phase 2

Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer

Recruiting
NCT05705466Phase 1

Study of Navtemadlin Plus Pembrolizumab as Maintenance Therapy in Locally Advanced and Metastatic Non-Small Cell Lung Cancer

Withdrawn
NCT02825836Phase 1

Phase I/II, FIH, Dose Escalation Trial of TL-895 and Expansion of TL-895 Monotherapy and Combination Therapy With Navtemadlin in Tx-Naïve and R/R CLL/SLL Subjects

Unknown

All 9 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
9